All In Biotech

Drug Trial Radar · NCT05262400

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

235

Actual

Start

Mar 14, 2022

Primary completion

Feb 26, 2027

Study completion Feb 26, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.

Conditions

  • Breast Cancer
  • Solid Tumors

Interventions

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

  • PF-07104091 + PF-07220060 + fulvestrant dose expansionDrug

    PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant

  • PF-07104091 + PF-07220060 + fulvestrant dose expansionDrug

    PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant

  • PF-07104091 + PF-07220060 + letrozole dose expansionDrug

    PF-07104091 and PF-07220060 will be administered orally in combination with letrozole

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

  • PF-07220060 + PF-07104091 combination dose escalationDrug

    PF-07104091 and PF-07220060 will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycleTime frame: Cycle 1 (28 days)
  2. Number of participants with treatment emergent adverse events (AEs)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
  3. Incidence of participants with clinical laboratory abnormalitiesTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
  4. Number of participants with vital signs abnormalitiesTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
  5. Number of participants with corrected QT (QTc) intervalTime frame: From baseline until end of study treatment or study completion (approximately 2 years)

Locations

44 sites in 9 countries. Site status is shown where the registry gives one.

  • Administrative Address: UCLA Hematology/Oncology

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • UCLA Hematology/Oncology

    Los Angeles, California

  • UCLA Hematology / Oncology-Parkside

    Santa Monica, California

  • UCLA Hematology/Oncology-Santa Monica

    Santa Monica, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • START Midwest

    Grand Rapids, Michigan

  • Saint Luke's Cancer Institute

    Kansas City, Missouri

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Swedish Medical Center

    Seattle, Washington

  • Swedish Medical Center

    Seattle, Washington

  • Centro Oncologico Korben

    Buenos Aires, Argentina

  • Clínica Universitaria Reina Fabiola

    Córdoba, Argentina

  • Fundación CORI para la Investigación y Prevención del Cáncer

    La Rioja, Argentina

  • Clinica Viedma S. A

    Viedma, Río Negro Province, Argentina

  • Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda

    São Paulo, Brazil

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia

    Ijuí, Rio Grande do Sul, Brazil

  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Pesquisa Clínica - Área Administrativa

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos

    Barretos, São Paulo, Brazil

  • Specialized Hospital for Active Treatment of Oncology - Haskovo

    Haskovo, Bulgaria

  • Complex Oncology Center - Plovdiv EOOD

    Plovdiv, Bulgaria

  • Complex Oncology Center - Vratsa

    Vratsa, Bulgaria

  • Multiprofile Hospital for Active Treatment Serdikamed EOOD

    Sofia, Sofia (stolitsa), Bulgaria

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Všeobecná fakultní nemocnice v Praze

    Prague, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Olomouc Region, Czechia

  • Fakultni nemocnice Bulovka

    Prague, Praha 8, Czechia

  • Instituto Nacional de Cancerologia

    Mexico City, Mexico City, Mexico

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

    Monterrey, Nuevo León, Mexico

  • Mérida Investigación Clínica

    Mérida, Yucatán, Mexico

  • FARMOVS

    Bloemfontein, Free State, South Africa

  • Wits Clinical Research

    Johannesburg, Gauteng, South Africa

  • Hospital Universitario Virgen Del Rocio

    Seville, Spain

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.